Related Experiment Video
Updated: Jan 26, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
A K M Nawshad Hossian1, Chandra Mohan Reddy Muthumula1, Md Sanaullah Sajib2
1School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe.
Abstract:
Lung cancer (LC) is the leading cause of cancer-related deaths worldwide. Similar to other cancer cells, a fundamental characteristic of LC cells is unregulated proliferation and cell division. Inhibition of proliferation by halting cell cycle progression has been shown to be a promising approach for cancer treatment, including LC. miRNA therapeutics have emerged as important post-transcriptional gene regulators and are increasingly being studied for use in cancer treatment. In recent work, we utilized two miRNAs, miR-143 and miR-506, to regulate cell cycle progression. A549 non-small cell lung cancer (NSCLC) cells were transfected, gene expression alterations were analyzed, and apoptotic activity due to the treatment was finally analyzed. Downregulation of cyclin-dependent kinases (CDKs) were detected (i.e., CDK1, CDK4 and CDK6), and cell cycle halted at the G1/S and G2/M phase transitions. Pathway analysis indicated potential antiangiogenic activity of the treatment, which endows the approach with multifaceted activity. Here, described are the methodologies used to identify miRNA activity regarding cell cycle inhibition, induction of apoptosis, and effects of treatment on endothelial cells by inhibition of angiogenesis. It is hoped that the methods presented here will support future research on miRNA therapeutics and corresponding activity and that the representative data will guide other researchers during experimental analyses.
Insights
This study shows that miR-143 and miR-506 can inhibit lung cancer cell proliferation by halting cell cycle progression. These microRNAs also induce apoptosis and show potential antiangiogenic activity, offering a multifaceted therapeutic approach.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Lung cancer (LC) remains a leading cause of cancer mortality globally.
- Unregulated cell proliferation is a hallmark of cancer, making cell cycle inhibition a key therapeutic strategy.
- MicroRNA (miRNA) therapeutics offer a novel approach to post-transcriptional gene regulation for cancer treatment.
Purpose of the Study:
- To investigate the efficacy of miR-143 and miR-506 in regulating cell cycle progression in non-small cell lung cancer (NSCLC) cells.
- To analyze the impact of these miRNAs on gene expression, apoptosis, and angiogenesis.
- To present methodologies for evaluating miRNA therapeutics in cancer research.
Main Methods:
- Transfection of A549 NSCLC cells with miR-143 and miR-506.
- Analysis of gene expression alterations, focusing on cell cycle regulators.
- Assessment of apoptotic activity and antiangiogenic effects on endothelial cells.
Main Results:
- Downregulation of key cyclin-dependent kinases (CDKs), including CDK1, CDK4, and CDK6, was observed.
- Cell cycle progression was halted at the G1/S and G2/M phase transitions.
- Pathway analysis suggested potential antiangiogenic activity, indicating multifaceted therapeutic potential.
Conclusions:
- miR-143 and miR-506 effectively inhibit NSCLC cell proliferation by targeting cell cycle progression.
- These miRNAs induce apoptosis and exhibit antiangiogenic properties, suggesting a dual therapeutic mechanism.
- The presented methodologies and data can guide future research in miRNA-based cancer therapeutics.
Related Concept Videos
02:33Combinatorial Gene Control
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
01:24Regulation of Angiogenesis and Blood Supply
01:22Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
01:04What is the Cell Cycle?
00:56What is the Cell Cycle?
01:28pH Regulation in Cells
Cytosolic pH
Under physiological conditions, the cytosolic pH is slightly more acidic than the extracellular pH. However, cells must prevent further acidification of their cytosol to...